CLA (Conjugated Linoleic Acid).

CLA is a polyunsaturated fatty acid, and its conjugated double bonds make it prone to lipid peroxidation once exposed to oxygen. Vitamin E is the body's main fat-soluble antioxidant, residing in the same lipid membranes and fat droplets to intercept the free radicals that would otherwise oxidize CLA, which is why the two are routinely formulated together.

CLA isomers are associated with higher carnitine palmitoyltransferase activity, and carnitine is the carrier that enzyme needs to move long-chain fatty acids into the mitochondrion. One raises demand at the shuttle, the other supplies it.

CLA and long-chain omega-3s compete for delta-6 desaturase and elongase capacity and for incorporation into the same membrane phospholipid positions. A large CLA dose lowers tissue EPA and DHA enrichment from a given fish oil intake.

GLA depends on delta-6 desaturase throughput, the same bottleneck CLA isomers interfere with. Combining the two in one softgel means they draw on a limited enzymatic capacity together.

CLA's conjugated double bonds are readily peroxidised, and ubiquinol works as a chain-breaking antioxidant inside the same lipid phase. CoQ10 also serves the electron transport chain that the extra fatty acid oxidation feeds.

Astaxanthin sits across the lipid bilayer and quenches radicals at both membrane surfaces, which is where conjugated dienes are vulnerable. It limits oxidation of the CLA both in the softgel and once incorporated.

Catechins act on catecholamine breakdown and thermogenesis while CLA acts on fat oxidation and adipocyte lipid handling. The two mechanisms are separate, which is why they are formulated together.

Caffeine raises cyclic AMP and drives triglyceride breakdown into free fatty acids, while CLA acts further along at the oxidation of those fatty acids. Release and disposal are complementary points in the chain.

Medium-chain triglycerides enter the mitochondrion without needing the carnitine shuttle, so they add oxidisable substrate alongside CLA's action on the long-chain route. They also serve as a carrier oil in the same softgel.

Phospholipid emulsifiers disperse CLA into finer droplets, which raises the surface available to pancreatic lipase and bile salts. It is a formulation-side effect on uptake rather than a metabolic one.

Conjugated linoleic acid shares the same carbon skeleton as linoleic acid, differing only in double-bond position and geometry. Industrial CLA is produced by isomerising linoleic acid from safflower or sunflower oil, so the two are directly related rather than independent nutrients. A person taking both is taking a parent fatty acid and its rearranged isomers together. This is a chemical relationship, not a demonstrated combined effect.

The conjugated diene that defines CLA is more prone to peroxidation than an ordinary methylene-interrupted double bond. Tocopherol donates a hydrogen atom to a lipid peroxyl radical and interrupts the propagation chain, which is why oil-filled capsules routinely carry it. The role here is protecting the oil in the capsule and in circulating lipids, not a separate physiological benefit.

Once a polyunsaturated fatty acid has already formed a hydroperoxide, glutathione peroxidase 4 is the enzyme that reduces it inside membranes, and that enzyme carries a selenocysteine residue. Adequate selenium is what allows that clean-up step to run at normal capacity. This supports normal handling of oxidised lipids rather than changing anything CLA itself does.

CLA supplied as a triglyceride needs pancreatic lipase to release the free fatty acids that enter the micelle and cross the enterocyte membrane. Free fatty acid preparations skip that step. Anyone with reduced pancreatic output is a case where the ester form and the free acid form behave differently, which is a formulation consideration and not a ranking.

Long-chain fatty acids including the CLA isomers depend on micellar solubilisation for uptake. Bile salts lower the interfacial tension of the fat droplet and give lipase a working surface. This is standard fat digestion, so the pairing matters most where bile flow is low.

Lecithin lowers the droplet size of an oil phase and keeps a CLA emulsion or powder from separating. It also contributes phosphatidylcholine, which the body uses in its own lipoprotein assembly. The contribution here is physical and formulatory.

Fat-soluble vitamins partition into the mixed micelle formed from dietary lipid. A CLA softgel supplies an oil phase, so co-ingestion gives vitamin D3 something to dissolve in. The effect is on absorption of the vitamin, not on anything CLA does.

MK-7 travels in chylomicrons and its uptake improves when taken with a lipid. An oil-based CLA capsule provides that lipid. The pairing is about the vehicle, and the amount of fat in one softgel is small.

Carotenoids are highly lipophilic and are poorly taken up from a fat-free meal. A fatty acid capsule contributes to micelle formation in the small intestine. This is a general fat effect that any dietary lipid shares.

CLA isomers and eicosapentaenoic acid are both incorporated into phospholipids and triglycerides by the same acyltransferases, so a large intake of one changes the fatty acid profile available to the other. Membrane fatty acid composition is a marker, not a clinical outcome. Formulators pairing the two should expect the tissue ratio to shift rather than simply add.

Docosahexaenoic acid and the CLA isomers both enter the phospholipid pool through acyl remodelling, and the pool is finite. Reported changes are in fatty acid composition, which is a marker. Both are polyunsaturated and both benefit from the same antioxidant protection in the capsule.

Krill oil supplies its fatty acids largely in phospholipid form, which disperses in the aqueous gut contents more readily than a neat triglyceride. Combining it with CLA is a formulation choice about dispersion. No combination trial is described here.